---

---

tags : Liver    entities : Aligos therapeutics, inc.   

save search

---

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| 19.51% | O: 7.34% H: 0.0% C: -20.0%
alg-0550 meeting liver favorable therapeutics

---

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| 8.44% | O: 0.0% H: 1.3% C: -9.26%
alg-0001 meeting hepatitis liver alg-000184 positive treatment therapeutics results

---

Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio
Published: 2023-11-07 (Crawled : 16:00) - biospace.com/
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| 9.87% | O: 5.13% H: 0.13% C: -7.88%
meeting liver therapeutics

---

Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C)
Published: 2023-11-07 (Crawled : 13:00) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| 9.87% | O: 5.13% H: 0.13% C: -7.88%
alg-0550 meeting hepatitis liver agonist treatment preclinical therapeutics

---

Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
Published: 2023-10-25 (Crawled : 12:00) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| 37.11% | O: 0.16% H: 3.13% C: 0.75%
alg-0001 meeting drug liver therapeutics

---

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
Published: 2023-06-21 (Crawled : 20:00) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| -17.33% | O: -0.99% H: 5.0% C: -2.87%
liver disease association therapeutics study

---

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
Published: 2023-06-07 (Crawled : 12:00) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| -29.24% | O: -1.69% H: 4.31% C: -2.59%
liver disease association therapeutics study

---

Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
Published: 2023-05-12 (Crawled : 21:00) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| Email alert Add to watchlist
liver biotech treatment research collaboration therapeutics agreement platform

---

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
Published: 2023-04-11 (Crawled : 23:00) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| -7.17% | O: 0.06% H: 7.22% C: 1.14%
hepatitis liver association therapeutics study

---

Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
Published: 2023-02-16 (Crawled : 18:00) - biospace.com/
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| -48.46% | O: 0.62% H: 12.88% C: 3.07%
liver conference association program therapeutics study

---

Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
Published: 2023-02-14 (Crawled : 15:20) - biospace.com/
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| -45.07% | O: -1.97% H: 9.4% C: 9.4%
liver conference association program therapeutics study

---

Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
Published: 2022-11-04 (Crawled : 12:20) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| -20.48% | O: 1.66% H: 3.99% C: -7.25%
meeting hepatitis liver program therapeutics nash chronic hepatitis b

---

Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
Published: 2022-10-21 (Crawled : 13:20) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| -23.39% | O: -1.83% H: 3.74% C: -2.8%
meeting hepatitis liver therapeutics nash chronic hepatitis b

---

Vipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver Diseases
Published: 2021-11-23 (Crawled : 13:00) - biospace.com/
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| -94.97% | O: -3.55% H: 0.56% C: -1.19%
disease liver disease partnership drug discovery drug research liver therapeutics infections

---

Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting® 2021
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| -95.16% | O: -2.26% H: 0.0% C: 0.0%
hepatitis nash liver chronic hepatitis b

---

Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD’S The Liver Meeting® 2021
Published: 2021-10-14 (Crawled : 21:00) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| -94.62% | O: 3.42% H: 1.68% C: -0.81%
hepatitis nash liver chronic hepatitis b

---

Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver
Published: 2021-02-03 (Crawled : 13:03) - globenewswire.com
ALGS | $0.781 -0.76% -0.77% 240K |

Health Technology

| -96.75% | O: 2.3% H: 0.0% C: -12.55%
hepatitis drug liver chronic hepatitis b

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---